Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
Alkermes, Inc.
ALKS
NASDAQ
A biopharmaceutical company developing treatments for central nervous system diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo pill aims to curb weight gain in teens on antipsychotics Results expected Sep 2026 (estimated)
- New pill aims to fight excessive daytime sleepiness Results expected Nov 2026 (estimated) May already have reported ↗
- New narcolepsy pill aims to banish daytime drowsiness Results expected May 2027 (estimated)
- New pill aims to fight daytime sleepiness and sudden muscle collapse Results expected May 2027 (estimated)
- New pill aims to keep narcolepsy patients awake and steady Results expected Jun 2027 (estimated)